Daclizumab Japanese PK Study

Healthy Clinical Trial

Official title:

A Single-Dose, Single-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB019, Daclizumab High Yield Process (DAC HYP), in Japanese and Caucasian Adult Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01929746
• Other study ID #: 205HV102
• Secondary ID: EUDRA CT NO: 201
• Status: Completed
• Phase: Phase 1
• First received: August 23, 2013
• Last updated: May 1, 2014
• Start date: October 2013
• Est. completion date: March 2014

Study information

• Verified date: May 2014
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to evaluate the pharmacokinetic (PK) profile of BIIB019 (Daclizumab High Yield Process; DAC HYP) administered as a single subcutaneous (SC) dose (75 mg or 150 mg) Japanese and Caucasian adult healthy volunteers. The secondary objective of this study in this study population is to assess the safety and tolerability of BIIB019 administered as a single SC dose (75 mg or 150 mg).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Key Inclusion Criteria:

• Japanese subjects must have been born in Japan, have both parents and grandparents of Japanese origin, and not have lived outside of Japan for more than 5 years or significantly modified their diets since leaving Japan.

• Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 4 months after their last dose of study treatment.

• Body mass index (BMI) within 18 to 30 kg/m2, inclusive.

• Nonsmoker or be willing to abstain from using tobacco and tobacco-containing products for 24 hours prior to clinic admission and during the In-Clinic Period and to smoke no more than 10 cigarettes per day throughout the remainder of the study.

• Must be willing to refrain from all alcohol consumption for 48 hours prior to Day 1 and during the In-Clinic Period and to limit the intake of alcohol to no more than 2 units per day throughout the remainder of the study.

Key Exclusion Criteria:

• History of a positive test result for human immunodeficiency virus (HIV) antibody.

• History of hepatitis or a positive test result for hepatitis C virus antibody (HCVAb) or hepatitis B virus antibody (test for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]).

• History of tuberculosis (TB) or a positive QuantiFERON®-TB Gold test. There must be no other clinical evidence of TB on physical examination of the subject. Note: Subjects who have had prior adequate prophylaxis treatment for latent TB with an appropriate course of isoniazid or equivalent, per country standards, are not excluded from study participation.

• Subjects with a history of carcinoma in situ and malignant disease, with the exception of basal cell carcinoma that has been completely excised prior to study, are not eligible.

• Treatment with any prescription medication within 2 weeks before Day -1 with the exception of oral contraceptives for women of childbearing potential.

• Treatment with any nonprescription medicinal products (including vitamin/mineral/herbal-containing preparations but excluding acetaminophen) within the 7 days prior to study treatment.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy

Intervention

Biological:
• BIIB019 subcutaneous injection
participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group

Locations

Country	Name	City	State
United Kingdom	Research Site	Leeds

Sponsors (2)

Lead Sponsor	Collaborator
Biogen	AbbVie

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the concentration-time curve from time 0 to infinity (AUCinf)		Up to Day 105	No
Primary	Maximum observed concentration (Cmax)		Up to Day 105	No
Primary	Time to reach maximum observed concentration (Tmax)		Up to Day 105	No
Primary	Terminal elimination half-life (t1/2)		Up to Day 105	No
Primary	Apparent volume of distribution (Vd/F)		Up to Day 105	No
Primary	Apparent clearance (CL/F)		Up to Day 105	No
Secondary	The number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)		Up to Day 105	Yes